Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brookfield Infrastructure Partners LP (BIP) vs Smith & Nephew plc (SNN) Price & Performance

Brookfield Infrastructure Partners LPTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Brookfield Infrastructure Partners LP vs Smith & Nephew plc — how do they compare? Brookfield Infrastructure Partners LP trades at $39 (market cap $18.10B), while Smith & Nephew plc trades at $29.95 (market cap $12.54B). The key difference: Brookfield Infrastructure Partners LP is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.62%). Which is the better fit depends on your goals.

BIPSNN
Market Cap
$18.10B$12.54B
Sector
IndustrialsHealth
52-Week High
$42.62$38.70
52-Week Low
$29.81$28.73
Enterprise Value
$77.05B$15.57B
Dividend Yield
4.62%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brookfield Infrastructure Partners LP

No Aura AI signal available yet.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.

Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.

Returns comparison

Trailing returns across standard periods

About Brookfield Infrastructure Partners LP

Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.

Read more on BIP

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN